Mereo BioPharma Group plc (MREO)
NASDAQ: MREO · Real-Time Price · USD
0.4944
+0.1100 (28.62%)
At close: Jan 9, 2026, 4:00 PM EST
0.4991
+0.0047 (0.95%)
After-hours: Jan 9, 2026, 7:59 PM EST
Mereo BioPharma Group Revenue
Mereo BioPharma Group had revenue of $500.00K in the twelve months ending September 30, 2025, down -50.00% year-over-year.
Revenue (ttm)
$500.00K
Revenue Growth
-50.00%
P/S Ratio
156.41
Revenue / Employee
$13,889
Employees
36
Market Cap
78.67M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 10.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 49.37M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
MREO News
- 11 days ago - These biotech stocks are getting hammered by shocking brittle-bone treatment study results - Market Watch
- 11 days ago - Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta - GlobeNewsWire
- 5 months ago - āshibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2 - Business Wire
- 5 months ago - Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights - GlobeNewsWire
- 6 months ago - Mereo BioPharma: Buy Rating Despite No Early Study Completion Of Setrusumab For OI - Seeking Alpha
- 8 months ago - Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights - GlobeNewsWire
- 10 months ago - Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights - GlobeNewsWire
- 11 months ago - Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference - GlobeNewsWire